Maze Therapeutics prices $150M registered offering; net proceeds ~$144.7M

Maze Therapeutics, Inc.

Offering of 5,540,000 shares at $23.50/share and 850,000 pre-funded warrants at $23.499 each.
Net proceeds of ~$144.7M to fund R&D for MZE829 (AMKD) and MZE782 (PKU, CKD) and general corporate purposes.
Expected to close April 23, 2026; Leerink Partners LLC is sole underwriter.
Participants include Farallon, T. Rowe Price, Frazier Life Sciences, Janus Henderson, and others.
Cash runway extended into 2029 based on current business plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.